CEL-SCI (NYSE:CVM) Lowered to “Sell” Rating by StockNews.com

CEL-SCI (NYSE:CVM) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Wednesday.

CEL-SCI Price Performance

NYSE:CVM opened at $0.60 on Wednesday. CEL-SCI has a 12 month low of $0.54 and a 12 month high of $3.23. The company has a current ratio of 0.64, a quick ratio of 0.18 and a debt-to-equity ratio of 1.00. The business’s 50-day moving average is $0.93 and its 200 day moving average is $1.13. The company has a market capitalization of $38.57 million, a P/E ratio of -1.04 and a beta of 0.69.

Institutional Investors Weigh In On CEL-SCI

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CVM. Tidal Investments LLC bought a new position in shares of CEL-SCI during the first quarter valued at approximately $27,000. Black Diamond Financial LLC grew its stake in shares of CEL-SCI by 35.8% during the second quarter. Black Diamond Financial LLC now owns 72,000 shares of the company’s stock valued at $84,000 after buying an additional 19,000 shares during the last quarter. Cutter & CO Brokerage Inc. grew its stake in shares of CEL-SCI by 29.4% during the second quarter. Cutter & CO Brokerage Inc. now owns 108,445 shares of the company’s stock valued at $126,000 after buying an additional 24,634 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of CEL-SCI by 29.9% during the second quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock valued at $202,000 after buying an additional 40,000 shares during the last quarter. Finally, Calton & Associates Inc. bought a new position in shares of CEL-SCI during the third quarter valued at approximately $50,000. 12.08% of the stock is currently owned by hedge funds and other institutional investors.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.